Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › MET Exon 14 Skipping Mutation

MET Exon 14 Skipping Mutation

2 published articles · Updated continuously

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Case report on sequential therapy for MET exon 14 skipping NSCLC with high PD-L1
Oncology Meta-analysis
Case report on sequential therapy for MET exon 14 skipping NSCLC with high PD-L1 A New Drug Sequence Shrank Lung Tumors When Others Failed
This is a case report with literature review of a 79-year-old male with MET exon 14 skipping non-small cell lung cancer and high PD-L1 expre…
A 79-year-old man's lung tumors shrank when doctors switched his drug sequence, offering a clue for others with hard-to-treat cancer.
Frontiers May 12, 2026
Capmatinib shows efficacy in Chinese NSCLC patients with MET exon 14 skipping mutations
Pulmonology & Critical Care Phase II
Capmatinib shows efficacy in Chinese NSCLC patients with MET exon 14 skipping mutations Could a targeted pill help Chinese patients with a specific lung cancer mutation?
An open-label, multicenter phase II study evaluated capmatinib in 36 Chinese adult patients with advanced NSCLC harboring MET exon 14 skippi…
A targeted pill shrank tumors in Chinese lung cancer patients with a specific MET gene mutation, offering a new treatment option for this ge…
CT.gov Mar 30, 2026